December 11th, 2017
jobs
homes

Menu
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

1,063.56 -21.63 (-1.99%)
Official Closing Price Updated: 7:00 PM EST, Jan 9, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
News headline image
Guidance Watch: 2 Companies Bullishly Raising Forecasts ↗
Several companies, including Palantir and Eli Lilly, have raised guidance, reflecting positivity surrounding their results. Let’s take a closer look at what drove the strong quarters. 
Via Talk Markets
News headline image
Eli Lilly Strikes $1.3 Billion Deal With Superluminal To Develop AI-Driven Obesity Drugs ↗
Eli Lilly and Co (NYSE: LLY) has entered into a $1.3 billion deal with Superluminal Medicines to develop small-molecule drugs through artificial intelligence (AI) to treat obesity and other... 
Via Benzinga
Topics Artificial Intelligence
News headline image
1 Healthcare Stock for Long-Term Investors and 2 We Ignore
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory destocking have harmed the... 
Via StockStory
Topics Stocks
News headline image
Stay informed with the top movers within the S&P500 index on Thursday. ↗
Join us in exploring the top gainers and losers within the S&P500 index one hour before the close of the markets on Thursday as we examine the latest happenings in today's session. 
Via Chartmill
Eli Lilly Inks Up To $1.3B Deal With Superluminal Medicines To Develop Obesity Drugs ↗
Via Stocktwits
News headline image
This Chinese EV-Maker Gets A Price Target Hike From JPMorgan, But Retail’s Concerned About The Stock’s Performance ↗
JPMorgan lifted fiscal 2026 and 2027 volume estimates for Nio by 11% to 13% on stronger volume from the company's new L90 and L80 SUV launches. 
Via Stocktwits
News headline image
Eli Lilly To Hike Mounjaro Prices By A Whopping 170% In UK: Retail Expects Stock To See Smooth Rally Till $720 ↗
According to the Financial Times, the price for a month’s supply of the highest doses of the drug will rise from £122 to £330, an increase of 170%. 
Via Stocktwits
Topics Government World Trade
News headline image
Eli Lilly Hikes UK Mounjaro Price By Up To 170% As Trump Pressure Mounts ↗
President Donald Trump is moving ahead with his Most Favored Nation pricing plan and Eli Lilly is playing ball. 
Via Investor's Business Daily
Topics Government
News headline image
These S&P500 stocks are moving in today's session ↗
Curious about the S&P500 stocks that are in motion on Thursday? Join us as we explore the top movers within the S&P500 index during today's session. 
Via Chartmill
News headline image
Eli Lilly & Co.: Deep Pullback Near 52‑Week Low Tests Strong Fundamentals And Bullish Analyst Targets ↗
LLY has given back meaningful ground over recent horizons: the stock is down approximately $103.94 (≈-13.6%) month-to-date and about $119.68 (≈-15.4%) year-to-date. 
Via Talk Markets
News headline image
Eli Lilly To Raise Mounjaro Price In UK, Expands Obesity Drug Push In India ↗
Eli Lilly will raise Mounjaro's UK price by 170% in September while launching its Kwikpen injector in India, intensifying competition with Novo Nordisk in the global obesity drug market. 
Via Benzinga
News headline image
5 Must-Read Analyst Questions From Eli Lilly’s Q2 Earnings Call
Eli Lilly delivered above-consensus results in the second quarter, surpassing Wall Street’s revenue and non-GAAP profit expectations, yet the market response was notably negative. Management attributed... 
Via StockStory
Topics Earnings
News headline image
3 Market-Beating Stocks to Keep an Eye On
Stocks that outperform the market usually share key traits such as rising sales, expanding margins, and increasing returns on capital. The select few that can do all three for many years are often the... 
Via StockStory
News headline image
Why Eli Lilly Stock Popped Today ↗
The GLP-1 weight loss wars have gone global. 
Via The Motley Fool
News headline image
Eli Lilly (LLY) Stock Trades Up, Here Is Why
Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 3.1% in the afternoon session after reports of significant insider buying by top executives, including the CEO, sent the stock... 
Via StockStory
News headline image
Weighing The Costs: Obesity Drug Users Make Financial Sacrifices As Coverage Tightens ↗
Doctors report insurance cuts are forcing many U.S. patients on Wegovy and Zepbound to pay high out-of-pocket costs. 
Via Benzinga
News headline image
Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst ↗
William Blair projects strong VENTURE-Oral trial results for Viking's VK2735, citing flexibility and market opportunity after a rival's setback. 
Via Benzinga
News headline image
How Novo Nordisk's Weight-Loss Drug Could Unlock A Better Future For Biogen's Alzheimer's Treatment ↗
Biogen CEO Chris Viehbacher says Novo Nordisk's Alzheimer's trial success could lead to combination therapies, boosting treatment options despite competition from Eli Lilly. 
Via Benzinga
News headline image
Nvidia To Rally Around 23%? Here Are 10 Top Analyst Forecasts For Wednesday ↗
 
Via Benzinga
News headline image
Texas Sues Eli Lilly For Alleged Kickback Scheme Involving Mounjaro, Zepbound ↗
Texas Attorney General Ken Paxton has sued Eli Lilly, alleging the drugmaker offered illegal incentives to providers, leading to millions in improper Medicaid claims. 
Via Benzinga
Topics Law Enforcement Lawsuit
News headline image
The 3 Things That Matter for Viking Therapeutics Now ↗
Enthusiasm for its weight loss medications is intensifying, and several companies are preparing oral formulations. 
Via The Motley Fool
News headline image
Here's How Much You Would Have Made Owning Eli Lilly Stock In The Last 15 Years ↗
 
Via Benzinga
News headline image
Texas Sues Eli Lilly Over Bribery Allegations: Retail Focuses On Company’s Upbeat Performance ↗
Texas Attorney General Ken Pax­ton alleged that Lilly offered illegal incentives to medical providers in Texas designed to steer providers toward prescribing Lilly’s drugs. 
Via Stocktwits
Topics Fraud Law Enforcement Lawsuit
News headline image
Top 5% Biotech, Insmed, Hits A Record High On Its 'Skeleton Key' Approval ↗
Insmed stock hit a record high Tuesday after the FDA approved its drug, brensocatib, for patients with a lung condition. 
Via Investor's Business Daily
News headline image
Hims & Hers Remains Outside Novo Nordisk's Growing Legal Storm For Now ↗
Novo Nordisk filed more Wegovy lawsuits against smaller U.S. firms, as the FDA sets a compounding deadline. Hims & Hers was not named in the new cases. 
Via Benzinga
Topics Lawsuit
News headline image
UK Government, Eli Lilly Partner To Target Obesity Health Gaps ↗
A UK government and Eli Lilly £85 million program will expand obesity care nationwide, offering digital, community, and pharmacy-based services by summer 2026. 
Via Benzinga
News headline image
Best Stock to Buy: Eli Lilly Stock vs. Novo Nordisk Stock ↗
Investors have a tough choice between these two excellent companies. 
Via The Motley Fool
News headline image
If You'd Invested $1,000 in Viking Therapeutics 3 Years Ago, Here's How Much You'd Have Today ↗
The biopharmaceutical company has an exciting lead compound in development. 
Via The Motley Fool
News headline image
1 Reason to Buy Eli Lilly (LLY) Stock ↗
There's a reason you might want to hold off on buying Lilly stock. 
Via The Motley Fool
Topics Government World Trade
News headline image
Cramer Expects This FinTech To Reach $100, Upset With Eli Lilly: 'Come Back And Talk To Me' ↗
Cramer says we are "too negative" on Eli Lilly. "I think they should come back on and talk to me," he adds. 
Via Benzinga
< Previous 1 2
...
30 31 32 33 34 35 36 37 38
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

More ways to get to us

Lethbridge Herald Facebook Facebook
Lethbridge Herald Twitter Twitter
Lethbridge Herald YouTube YouTube

About Us

Contact the Lethbridge Herald

504 - 7th Street South
Lethbridge, AB T1J 3Z7

[P] (403) 328-4411
[F] (403)328-4536

Print Advertising: (403) 328-4410
National Advertising: (403) 380-7585
Online Advertising: (403) 380-7585
Classifieds: (403) 328-4433

© 1996-2017 The Lethbridge Herald, A Division of Continental Newspapers Canada Ltd.